Lindsey Shapiro, PhD, science writer —

People from ethnic minority backgrounds were significantly less likely to be eligible for the cystic fibrosis therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor) than white patients, according to a recent U.K. study. Given that the therapy is the most effective CF therapy on the market, “the CF community should urgently address the…

Several potential biomarkers of nontuberculosis mycobacteria (NTM)-associated lung disease were identified in the breath of people with cystic fibrosis (CF) in a recent pilot study. The approach may offer a faster way of reaching an NTM diagnosis, which has historically relied on slow bacterial culture techniques that sometimes delay…

The presence of lung disease was low among infants with cystic fibrosis (CF) and was not associated with respiratory infections, yet respiratory symptoms, like cough or wheezing, may be a sign that lung disease is progressing, according to a recent study. “Respiratory symptoms in infants with CF deserve attention…

A noninvasive imaging technique called elastography can detect the degree of liver fibrosis, or scarring, in children with cystic fibrosis (CF), according to a recent study. Combining the technique with other laboratory tests in clinical practice might allow for the early diagnosis and treatment of liver disease in these…

The Cystic Fibrosis Foundation (CFF) has awarded $1.6 million to support research focused on identifying biomarkers of chronic lung allograft dysfunction (CLAD) — a complication of lung transplants — in people with cystic fibrosis (CF). A total of eight grants have been awarded, which will each focus on…

A noninvasive measurement of lung function called lung clearance index (LCI) was associated with the degree of lung damage over time in children with cystic fibrosis (CF), according to a recent study. LCI could be used to monitor lung disease progression in children with CF and may help clinicians…

The Cystic Fibrosis Foundation (CFF) has awarded up to $15.9 million to Eloxx Pharmaceuticals to support the company’s clinical program for ELX-02, an investigational therapy for cystic fibrosis (CF) patients with nonsense mutations. A total of $7 million will be provided upfront, with additional funding granted based on…

Beginning April 1 the Australian government will subsidize the cost of Trikafta (elexacaftor/tezacaftor/ivacaftor) for patients with cystic fibrosis (CF) under the Australian Pharmaceutical Benefits Scheme (PBS), dramatically reducing out-of-pocket expenses for eligible Australians. The subsidy was made possible by a reimbursement agreement reached between Trikafta’s developer, Vertex…

Levels of several metabolites were associated with inflammation and the presence of bacteria in the lower airways of people with cystic fibrosis (CF), which could be used as disease biomarkers, according to a recent study. “Our study was the first to both examine these metabolites in lower airway samples and…

The nonprofit Emily’s Entourage has awarded $440,000 in funding to support two projects aimed at advancing cystic fibrosis (CF) research. “These grants reflect Emily’s Entourage’s unwavering commitment to advance lifesaving research to fill critical unmet needs and expeditiously pursue promising therapeutic opportunities for the CF community, especially those that…